Abstract:This paper studies novel techniques for synthesizing 3‐Amino‐5,6‐Dimethyl‐l,2,4‐triazine, and new l,2,4‐triazine derivatives under free solvent conditions. All the target compounds were synthesized in accepTable quantities. Furthermore, NCI selected some of the synthesized compounds to test for potential in vitro anticancer activity against a panel of sixty human cancer cell lines covering nine tumor panels. Two effective one‐pot synthesis procedures were proposed for the synthesis of 3‐amino‐5,6‐dimethyl‐l,2,4‐triazine under free solvent conditions; these methods included fusing the monohydrazide of biacetyl with either methyl carbamimidothioate (Method B) or cyanamide (Method C). Simple reaction conditions, an easy work‐up process, and facile separation characterize the ecologically friendly fusion process used in techniques B and C. The results from methods B and C indicated the existence of amino‐imino prototropic tautomerism. The triazine in method C had a different melting point and had unusual mass spectral behavior, suggesting that it was in the imino‐tautomer form, as opposed to the amino‐tautomer form discovered in procedure B. The strong electron‐withdrawing activity of the triazine ring appears to deactivate the 3‐amino group, which in turn triggers the production of additional triazine derivatives (3–12), with yields ranging from 54% to 82%. To characterize the structure of the newly synthesized compounds, 1H, 13C‐NMR, and mass spectrometry were employed. The compounds that were created underwent testing at the National Cancer Institute. According to the screening results, conjugates 9 and 10 were successful against most of the cancer cell line subpanels. With the use of DFT, we conducted theoretical studies on compounds 9 and 10. Topological studies, including ELF, LOL, and RDG, were used to identify the main binding sites and weak interactions of the target derivatives. The synthesized compounds that have promising properties are subjected to a pharmacological examination using Swiss‐ADME. Cox‐1 (PDB ID: 3KK6) is the target of molecular docking experiments that aim to identify the anticancer active site of the derivatives of interest.

Discovery of novel thiazolidinone-1,2,3-triazole hybrids with (D)-Limonene skeleton as anticancer agents: Design, synthesis and biological evaluation

Design, Synthesis, and Anticancer Activity Evaluation of Hybrids of Azoles and Barbituric Acids.

Design of New Benzo[h]chromene Derivatives: Antitumor Activities and Structure-Activity Relationships of the 2,3-Positions and Fused Rings at the 2,3-Positions

Targeted synthesis via the structure-activity relationship: Biological evaluation of new 1,2,3-triazoles monoterpene as antitumor agents

Design and Click Synthesis of Novel 1- Substituted-4-(3,4-Dimethoxyphenyl)-1H-1,2,3-Triazole Hybrids for Anticancer Evaluation and Molecular Docking

Hybrids of thiazolidinone with 1,2,3-triazole derivatives: design, synthesis, biological evaluation, in silico studies, molecular docking, molecular dynamics simulations, and ADMET profiling

New 1,2,3-Triazole-Containing Hybrids as Antitumor Candidates: Design, Click Reaction Synthesis, DFT Calculations, and Molecular Docking Study

Synthesis, Molecular Docking and Antitumor Activity of New Dithiazoles

Rational design of 1,2,3-triazole hybrid structures as novel anticancer agents: synthesis, biological evaluation and molecular docking studies

Synthesis and Reactions of 3‐Amino‐5,6‐Dimethyl‐l,2,4‐Triazine: DFT Studies, ADME Assay, and Molecular Docking on the new l,2,4‐Triazine Derivatives as Anticancer Agents.

Copper(I)-Catalyzed Regioselective Synthesis of 1,2,3-Triazole–Phthalazine-1,4-dione Hybrids, and Their Anticancer and Molecular Docking Studies

Thiazolidinone-linked-1,2,3-triazoles with (R)-Carvone as new potential anticancer agents

Designing Potent Anti-Cancer Agents: Synthesis and Molecular Docking Studies of Thieno[2,3-d][1,2,4]triazolo[1,5-a]pyrimidine Derivatives

A novel D-limonene derivative: synthesis, characterization, molecular docking, molecular dynamics and ADMET prediction studies

Synthesis, Biological Evaluation and Molecular Docking Study of Novel Benzhydryl Piperazine‐1,2,3‐Triazoline Hybrids

Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study

Synthesis and Anticancer Activity of 5-[(1-Aryl-1H-1,2,3-triazol-4-yl)methyl]-10,11-dihydro-5H-dibenzo[b,f]azepines

Design, synthesis, and in vitro and in vivo biological evaluation of triazolopyrimidine hybrids as multitarget directed anticancer agents

Click chemistry-based synthesis of new 1,2,3-triazolo-benzoquinoline-3-carbonitriles: anticancer screening and DFT studies

Parallel Synthesis of Novel Antitumor Agents: 1,2,3-Triazoles Bearing Biologically Active Sulfonamide Moiety and Their 3D-QSAR

Novel Coumarin‐Pyrazole‐Thiazoles Hybrids: Synthesis, Anticancer Activity, Molecular Docking and In Silico ADMET prediction Studies